GERD in Children With Cystic Fibrosis
Launched by DUKE UNIVERSITY · Sep 25, 2024
Trial Information
Current as of June 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at children with Cystic Fibrosis (CF) who also have a condition called gastroesophageal reflux disease (GERD), which can cause symptoms like heartburn and discomfort. The study aims to understand how these symptoms change when children stop taking their GERD medications after being treated for a while. Researchers will use surveys to gather information about the children’s reflux symptoms during this time.
To participate in the study, children need to be between 6 and 17 years old and have a confirmed diagnosis of Cystic Fibrosis. They should also have been on a stable dose of GERD medication for at least three months. It’s important for parents to know that children who have severe GERD or are not willing to stop their medications cannot take part in this trial. If eligible, participants will be asked to stop their GERD treatment and complete surveys about their symptoms, helping doctors learn more about managing GERD in children with Cystic Fibrosis.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Children 6-17 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
- • GERD medications documented at visit 1
- • Stable GERD medication dose for 3 months
- • Pediatric GERD Symptom Assessment Score \<80
- • Signed consent
- Exclusion Criteria:
- • Declining to participate in the study or sign consent
- • Unwillingness to stop GERD therapy
- • History of severe GERD per gastroenterology diagnosis and documentation
- • GSAS score \>80
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Durham, North Carolina, United States
Patients applied
Trial Officials
Shatha Yousef
Principal Investigator
Duke University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported